Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | 3 | 1 | 4 | 9 |
Hemophilia b | D002836 | — | D67 | 1 | — | 3 | 1 | 4 | 9 |
Drug common name | Eftrenonacog alfa |
INN | eftrenonacog alfa |
Description | Alprolix (eftrenonacog alfa) is a fusion protein pharmaceutical. Eftrenonacog alfa was first approved as Alprolix on 2016-05-12. It has been approved in Europe to treat hemophilia b. |
Classification | Fusion protein |
Drug class | Fc fusion protein |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594598 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 02E00T2QDE (ChemIDplus, GSRS) |